183 related articles for article (PubMed ID: 2519893)
1. Platelet-activating factor (PAF) antagonistic actions of two new analogs of tetrahydrofurans.
Tsao PS; Stahl GA; Lefer AM; Salvino J; Pietranico S; Nicolaou KC
J Lipid Mediat; 1989; 1(3):189-99. PubMed ID: 2519893
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models.
Nagaoka J; Harada K; Kimura A; Kobayashi S; Murakami M; Yoshimura T; Yamada K; Asano O; Katayama K; Yamatsu I
Arzneimittelforschung; 1991 Jul; 41(7):719-24. PubMed ID: 1663352
[TBL] [Abstract][Full Text] [Related]
4. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo.
Terashita Z; Imura Y; Takatani M; Tsushima S; Nishikawa K
J Pharmacol Exp Ther; 1987 Jul; 242(1):263-8. PubMed ID: 3612533
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships in platelet-activating factor (PAF antagonists). 6. Synthesis and in vitro antagonistic activities of 2-substituted 5-oxotetrahydrofurans.
Favre E; Heymans F; Redeuilh C; Batt JP; Massicot F; Blavet N; Braquet P; Godfroid JJ
J Lipid Mediat; 1992 Feb; 5(1):23-40. PubMed ID: 1449553
[TBL] [Abstract][Full Text] [Related]
6. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J
J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
[TBL] [Abstract][Full Text] [Related]
7. [Effects of ketotifen on rabbit platelet aggregation and platelet activating factor formation from rat neutrophils].
Wang XD; Bian RL
Zhongguo Yao Li Xue Bao; 1990 Nov; 11(6):524-7. PubMed ID: 2130617
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological profile of epiyangambin: a furofuran lignan with PAF antagonist activity.
Castro-Faria-Neto HC; Martins MA; Silva PM; Bozza PT; Cruz HN; de Queiroz-Paulo M; Kaplan MA; Cordeiro RS
J Lipid Mediat; 1993 May; 7(1):1-9. PubMed ID: 8358020
[TBL] [Abstract][Full Text] [Related]
9. Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions: (II). Antagonistic effect of epinastine on chemical mediators, mainly antihistaminic and anti-PAF effects.
Kamei C; Mio M; Kitazumi K; Tsujimoto S; Yoshida T; Adachi Y; Tasaka K
Immunopharmacol Immunotoxicol; 1992; 14(1-2):207-18. PubMed ID: 1350791
[TBL] [Abstract][Full Text] [Related]
10. MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor.
Hwang SB; Lam MH; Szalkowski DM; MacIntyre DE; Bach TJ; Luell S; Meuer R; Sahoo SP; Alberts AW; Chabala JC
J Lipid Mediat; 1993 Jun; 7(2):115-34. PubMed ID: 8400114
[TBL] [Abstract][Full Text] [Related]
11. Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist.
Hwang SB; Li CL; Lam MH; Shen TY
Lab Invest; 1985 Jun; 52(6):617-30. PubMed ID: 3925239
[TBL] [Abstract][Full Text] [Related]
12. Platelet-activating factor (PAF) mediation of rat anaphylactic responses to soluble immune complexes. Studies with PAF receptor antagonist L-652,731.
Doebber TW; Wu MS; Biftu T
J Immunol; 1986 Jun; 136(12):4659-68. PubMed ID: 3011900
[TBL] [Abstract][Full Text] [Related]
13. Effects of a platelet-activating factor antagonist, CV-3988, on different shock models in the rat.
Toth PD; Mikulaschek AW
Circ Shock; 1986; 20(3):193-203. PubMed ID: 3802423
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity.
Parry MJ; Alabaster VA; Cheeseman HE; Cooper K; deSouza RN; Keir RF
J Lipid Mediat Cell Signal; 1994 Sep; 10(3):251-68. PubMed ID: 7812676
[TBL] [Abstract][Full Text] [Related]
15. Effects of tetrandrine on rabbit platelet aggregation and platelet activating factor generation.
Zhang M; Zhang LZ; Lu JS
Zhongguo Yao Li Xue Bao; 1995 May; 16(3):209-12. PubMed ID: 7660812
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor.
Hwang SB; Lam MH; Alberts AW; Bugianesi RL; Chabala JC; Ponpipom MM
J Pharmacol Exp Ther; 1988 Aug; 246(2):534-41. PubMed ID: 2841449
[TBL] [Abstract][Full Text] [Related]
17. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
Imanishi N; Murakami-Uchida M; Koike H; Natsume Y; Morooka S
Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
[TBL] [Abstract][Full Text] [Related]
18. 4-substituted 2-alkoxytetrahydrofurans as potent and long-lasting PAF antagonists.
Carceller E; Merlos M; Giral M; Bartrolí J; García-Rafanell J; Forn J
J Med Chem; 1992 Feb; 35(4):676-83. PubMed ID: 1542094
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of the Korean herbal medicine, Dae-Jo-Whan, on platelet-activating factor-induced platelet aggregation.
Chang GT; Kang SK; Kim JH; Chung KH; Chang YC; Kim CH
J Ethnopharmacol; 2005 Dec; 102(3):430-9. PubMed ID: 16125889
[TBL] [Abstract][Full Text] [Related]
20. Receptor-mediated and protein kinase-dependent growth enhancement of primary human fibroblasts by platelet activating factor.
Bennett SA; Birnboim HC
Mol Carcinog; 1997 Dec; 20(4):366-75. PubMed ID: 9433481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
